Antidepressant switching among adherent patients treated for depression

Psychiatric Services

Volumn 60, Issue 5, 2009, Pages 617-623

  Marcus, Steven C ^a   Hassan, Mariam ^b   Olfson, Mark ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY TREATMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH CARE; OUTPATIENT; PATIENT COMPLIANCE; PRESCRIPTION; RISK; TREATMENT DURATION;

EID: 66249140570     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.5.617     Document Type: Article

References (46)

1. Thase ME, Rush AJ: Treatment-resistant depression, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven, 1995
2. Kroenke K, West SL, Swindle R, et al: Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286:2947-2955, 2001
3. Trivedi MH, Rush AJ, Wisniewski SR, et al: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163:28-40, 2006
4. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 157(Apr suppl):1-45, 2000
5. Treatment of Major Depression: Clinical Practice Guidelines 5, Vol 2. Rockville, Md, US Department of Health and Human Services, Agency for Healthcare Policy and Research, 1993
6. Rush AJ, Crismon ML, Toprac MG, et al: Consensus guidelines in the treatment of major depressive disorder. Journal of Clinical Psychiatry 59(suppl 20):73-84, 1998
7. Bauer M, Dopfer S: Lithium augmentation in treatment-resistant depression: metaanalysis of placebo-controlled trials. Journal of Clinical Psychopharmacology 19:427-434, 1999
8. Jackson IM: Does thyroid hormone have a role as adjunctive therapy in depression? Thyroid 6:63-67, 1996
9. Shelton R, Tollefson G, Tohen M, et al: A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 158:131-135, 2001
10. Ruhe HG, Huyser J, Swinkels JA, et al: Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Journal of Clinical Psychiatry 67:1836-1855, 2006
11. Rush AJ, Trivedi MH, Wisniewski SR, et al: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354:1231-1242, 2006
12. Thase M, Rush A, Kornstein S, et al: Doubleblind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry 59:233-239, 2002
13. Bull SA, Hunkeler EM, Lee JY, et al: Discontinuing or switching selective serotoninreuptake inhibitors. Annals of Pharmacotherapy 36:578-584, 2002
14. Shergill SS, Katona CL: Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. Journal of Affective Disorders 43:19-25, 1997
15. Byrne S, Rothschild AJ: Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatric Services 48:835-837, 1997
16. Mischoulon D, Nierenberg AA, Kizilbash L, et al: Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Canadian Journal of Psychiatry 45:476-481, 2000
17. Simon GE, Heiligenstein J, Revicki D, et al: Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Archives of Family Medicine 8:319-325, 1999
18. Keen MS, Eaddy MT, Nelson WW, et al: Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. American Journal of Managed Care 11(suppl 12):S362-S369, 2005
19. Jones LE, Turvey C, Carney-Doebbeling C: Inadequate follow-up care for depression and its impact on antidepressant treatment duration among veterans with and without diabetes mellitus in the Veterans Health Administration. General Hospital Psychiatry 28:465-474, 2006
20. Kupfer DJ: Long-term treatment of depression. Journal of Clinical Psychiatry 52(suppl): 28-34, 1991
21. Rogelio A, Fresan A, Rosa-Elena U, et al: Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology 30:2236-2244, 2005
22. James SP, Mendelson WB: The use of trazodone as a hypnotic: a critical review. Journal of Clinical Psychiatry 65:752-755, 2004
23. Roth R, Rogowski R, Hull S, et al: Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30:1555-1561, 2007
24. Kerr JS, Fairweather DB, Hindmarch I: Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients. International Clinical Psychopharmacology 8:341-343, 1993
25. Mouret J, Lemoine P, Minuit MP, et al: Sleep polygraphic effects of trimipramine in depressed patients: preliminary report. Drugs 38(suppl 1):14-16, 1989
26. Wezenberg E, Sabbe BG, Hulstijn W, et al: The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions. Journal of Psychopharmacology 21:579-587, 2007
27. Fava M: New approaches to the treatment of refractory depression. Journal of Clinical Psychiatry 61(suppl 1):26-32, 2000
28. Dodd S, Horgan D, Mahli G, et al: To combine or not combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders 89:1-11, 2005
29. Charlson ME, Pomei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Disease 40:373-383, 1987
30. Deyo RA, Cherkin D, Ciol MA: Adapting a clinical comorbidity index for use with ICD- 9-CM administrative databases. Journal of Clinical Epidemiology 45:613-619, 1992
31. Oquendo MA, Baca-Garcia E, Kartachov A, et al: A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Journal of Clinical Psychiatry 64:825-833, 2003
32. Busch SH, Leslie DL, Rosenheck RA: Comparing the quality of antidepressant pharmacotherapy in the department of Veterans Affairs and the private sector. Psychiatric Services 55:1386-1391, 2004
33. Bull SA, Hu XH, Hunkeler EM, et al: Discontinuation of use and switching of antidepressants influence of patient-physician communication. JAMA 288:1403-1409, 2002
34. Eaddy MT, Druss BG, Sarnes W, et al: Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy: results from a managed care administrative claims database. Journal of Managed Care Pharmacy 11:145-150, 2005
35. Simon G, VonKorff M, Leiligenstein JH, et al: Initial antidepressant selection in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275:1897-1902, 1996
36. Croghan TW, Lair TJ, Engelhart L, et al: Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatric Services 48:1420-1426, 1997
37. Mayers AG, Baldwin DS: Antidepressants and their effect on sleep. Human Pychopharmacology 20:533-559, 2005
38. Biswas PN, Wilton LV, Shakir SA: The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. Journal of Psychopharmacology 17:121-126, 2003
39. Mackay FR, Dunn NR, Martin RM, et al: Newer antidepressants: a comparison of tolerability in general practice. British Journal of General Practice 49:892-896, 1999
40. Dew RE, Kramer SI, McCall WV: Adequacy of antidepressant treatment by psychiatric residents: the antidepressant treatment history form as a possible assessment tool. Academic Psychiatry 29:283-288, 2005
41. Mulsant BH, Haskett RF, Prudic J, et al: Low use of neuroleptic drugs in the treatment of psychotic major depression. American Journal of Psychiatry 154:559-561, 1997
42. Shasha M, Lyons JS, O'Mahoney MT, et al: Serotonin reuptake inhibitors and the adequacy of antidepressant treatment. International Journal of Psychiatry and Medicine 27:83-92, 1997
43. Hodgkin D, Horgan CM, Garnick DW, et al: Management of access to branded psychotropic medications in private health plans. Clinical Therapeutics 29:371-380, 2007
44. Landsman PB, Yu W, Liu X, et al: Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. American Journal of Managed Care 11:621-628, 2005
45. Keks NA, Burrows GD, Copolov DL, et al: Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? Medical Journal of Australia 186:142-144, 2007
46. Stahl SM: Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. Journal of Clinical Psychiatry 59(suppl 18):23-29, 1998